Sunflower Pharmaceutical announced that Luling Sunflower, a wholly-owned subsidiary of the company, transferred the marketing license for mesalazine enteric tablets held by Cube Pharmaceuticals for 34 million yuan and related production technology. This transfer involves a change in the marketing license holder, which is subject to approval by the State Drug Administration, and does not constitute a related transaction or major asset restructuring. The deal aims to implement the “one old” strategy, enrich the product pipeline, and consolidate the advantages of digestive system medication. The contract was paid in three installments until the listing license holder changed to Luling Sunflower and the production site was changed or increased to the designated site, and the three batches of production were verified and the inspection passed.

Sunflower Pharmaceutical announced that Luling Sunflower, a wholly-owned subsidiary of the company, transferred the marketing license for mesalazine enteric tablets held by Cube Pharmaceuticals for 34 million yuan and related production technology. This transfer involves a change in the marketing license holder, which is subject to approval by the State Drug Administration, and does not constitute a related transaction or major asset restructuring. The deal aims to implement the “one old” strategy, enrich the product pipeline, and consolidate the advantages of digestive system medication. The contract was paid in three installments until the listing license holder changed to Luling Sunflower and the production site was changed or increased to the designated site, and the three batches of production were verified and the inspection passed.